Eloxx Pharmaceuticals, Inc.
ELOXHealthcare|Biotechnology|US
$12.44
-0.36 (-2.81%)
DCF Value
$1.22
Tangible Book / Share
$6.84
Cash / Share
$9.13
Financials
Financial Snapshot
Market Cap
$42.7M
Enterprise Value
-$19.2M
Revenue (TTM)
$0.00
Net Income (TTM)
-$11.9M
Cash & Investments
$62.0M
Net Cash
$62.0M
Free Cash Flow (TTM)
-$10.8M
Operating CF (TTM)
-$10.8M
Debt/Equity
0.00
Cash Runway & Burn Rate
Cash on Hand
$62.0M
Quarterly Burn
$2.7M
Monthly Burn
$899.3K
Est. Runway
~23.0 quarters
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $810.8K | $24.2M | $48.7M | $56.3M | $24.7M | $42.6M | $19.5M | $1.1M | $111.0K | $4.8M | $62.0M | |
| Operating Cash Flow | -$3.7M | -$15.9M | -$31.4M | -$39.4M | -$28.2M | -$35.0M | -$31.8M | -$14.3M | -$4.7M | -$6.3M | -$10.8M | |
| Free Cash Flow | -$3.7M | -$16.2M | -$31.6M | -$39.4M | -$28.2M | -$35.1M | -$31.9M | -$14.3M | -$4.7M | $0.00 | -$10.8M | |
| Capital Expenditure | -$5.00 | -$237.0K | -$235.0K | -$40.0K | $0.00 | -$89.0K | -$66.0K | $0.00 | $0.00 | $6.3M | $0.00 | |
| Financing Cash Flow | $1.2M | $37.9M | $56.2M | $46.8M | -$3.4M | $50.8M | $8.8M | -$4.1M | $3.4M | $11.0M | $68.4M |
R&D Spending
R&D (TTM)
$5.9M
R&D Intensity
—
R&D Growth vs Prior
+93.3%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $75.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $6.4M | $0.00 | $0.00 | |
| R&D Expense | $2.1M | $16.4M | $20.5M | $25.8M | $14.6M | $22.9M | $23.7M | $8.6M | $3.6M | $3.1M | $5.9M | |
| R&D % of Revenue | 2786.1% | — | — | — | — | — | — | — | 56.3% | — | — | |
| SG&A | $1.4M | $4.0M | $26.3M | $24.2M | $14.3M | $18.5M | $10.0M | $8.7M | $5.3M | $3.4M | $5.1M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $75.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $6.4M | $0.00 | $0.00 | |
| Cost of Revenue | $93.4K | $39.0K | $216.0K | $559.0K | $571.0K | $960.0K | $695.0K | $0.00 | $0.00 | $0.00 | $0.00 | |
| Gross Profit | -$18.4K | -$39.0K | -$216.0K | -$559.0K | -$571.0K | -$960.0K | -$695.0K | $0.00 | $6.4M | $0.00 | $0.00 | |
| R&D | $2.1M | $16.4M | $20.5M | $25.8M | $14.6M | $22.9M | $23.7M | $8.6M | $3.6M | $3.1M | $5.9M | |
| SG&A | $1.4M | $4.0M | $26.3M | $24.2M | $14.3M | $18.5M | $10.0M | $8.7M | $5.3M | $3.4M | $5.1M | |
| Operating Income | -$3.7M | -$20.4M | -$47.0M | -$50.6M | -$29.4M | -$42.3M | -$34.4M | -$17.3M | -$2.5M | -$6.4M | -$11.0M | |
| Interest Expense | $0.00 | $668.0K | $7.0K | $1.6M | $1.4M | $1.3M | $1.9M | $1.2M | $1.1M | $1.0M | $828.0K | |
| Pretax Income | -$8.9M | -$21.2M | -$47.1M | -$50.9M | -$34.6M | -$66.7M | -$36.1M | -$17.1M | -$3.1M | -$6.0M | -$11.9M | |
| Net Income | -$8.3M | -$21.2M | -$47.2M | -$50.9M | -$34.6M | -$66.7M | -$36.1M | -$17.1M | -$3.1M | -$6.0M | -$11.9M | |
| EPS (Diluted) | -3696.00 | -2090.00 | -640.06 | -588.09 | -379.16 | -419.65 | -183.13 | -72.93 | -9.24 | -5.34 | -11.92 | |
| EBITDA | -$3.6M | -$20.4M | -$46.8M | -$50.0M | -$28.9M | -$64.5M | -$33.5M | -$15.1M | -$1.8M | -$4.9M | -$11.0M | |
| Shares Out. (M) | 0.00 | 0.01 | 0.07 | 0.09 | 0.09 | 0.16 | 0.20 | 0.23 | 0.34 | 1.12 | 6.79 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $810.8K | $24.2M | $48.7M | $22.5M | $24.7M | $42.6M | $19.5M | $1.1M | $111.0K | $4.8M | $62.0M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $33.8M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $982.6K | $24.5M | $50.3M | $57.7M | $25.9M | $43.5M | $20.1M | $1.5M | $3.0M | $5.3M | $63.4M | |
| Total Assets | $9.2M | $24.8M | $50.7M | $58.9M | $26.5M | $45.1M | $21.1M | $1.7M | $3.0M | $5.3M | $63.4M | |
| Total Current Liabilities | $369.0K | $3.4M | $7.8M | $11.8M | $9.8M | $10.0M | $23.1M | $22.7M | $27.3M | $17.2M | $17.0M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $10.5M | $6.4M | $12.0M | $8.6M | $1.6M | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $4.7M | $3.4M | $7.8M | $22.7M | $16.2M | $22.8M | $31.8M | $24.3M | $27.3M | $17.2M | $17.0M | |
| Stockholders' Equity | $4.6M | $21.4M | $42.9M | $36.2M | $10.2M | $22.4M | -$10.7M | -$22.6M | -$24.3M | -$11.9M | $46.4M | |
| Retained Earnings | -$115.6M | -$39.0M | -$86.1M | -$137.0M | -$171.6M | -$238.3M | -$274.4M | -$291.4M | -$294.6M | -$300.6M | -$308.8M |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$3.7M | -$15.9M | -$31.4M | -$39.4M | -$28.2M | -$35.0M | -$31.8M | -$14.3M | -$4.7M | -$6.3M | -$10.8M | |
| Capital Expenditure | -$5.00 | -$237.0K | -$235.0K | -$40.0K | $0.00 | -$89.0K | -$66.0K | $0.00 | $0.00 | $6.3M | $0.00 | |
| Free Cash Flow | -$3.7M | -$16.2M | -$31.6M | -$39.4M | -$28.2M | -$35.1M | -$31.9M | -$14.3M | -$4.7M | $0.00 | -$10.8M | |
| Investing Cash Flow | $0.00 | -$114.0K | -$317.0K | -$33.5M | $33.8M | $2.1M | -$66.0K | $309.0K | $38.0K | $1.0K | $0.00 | |
| Financing Cash Flow | $1.2M | $37.9M | $56.2M | $46.8M | -$3.4M | $50.8M | $8.8M | -$4.1M | $3.4M | $11.0M | $68.4M | |
| Issuance of Stock | $1.2M | $38.0M | $54.0M | $33.1M | $71.0K | $47.7M | $0.00 | $4.9M | $0.00 | $0.00 | $131.0K | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $0.00 | -$64.0K | $0.00 | $14.7M | -$3.8M | $491.0K | $0.00 | -$9.4M | $3.1M | $1.6M | $1.0M | |
| Stock Based Comp. | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $2.0M | $541.0K | $235.0K | $177.0K | |
| Net Change in Cash | -$2.5M | $23.3M | $24.5M | -$26.1M | $2.2M | $17.8M | -$23.1M | -$18.1M | -$1.2M | -$14.7M | $57.4M |
Dilution Tracker
Shares outstanding grew 1130.9% over 5 years — significant dilution
Shares Outstanding
3M
5-Year Share Growth
+1130.9%
Stock Issuance (TTM)
$131.0K
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.00 | 0.01 | 0.07 | 0.09 | 0.09 | 0.16 | 0.20 | 0.23 | 0.34 | 1.12 | 6.79 | |
| Change vs Prior % | — | 389.8% | 551.9% | 17.3% | 5.4% | 74.4% | 23.9% | 18.7% | 46.2% | 228.5% | 504.8% | |
| Stock Issuance | $1.2M | $38.0M | $54.0M | $33.1M | $71.0K | $47.7M | $0.00 | $4.9M | $0.00 | $0.00 | $131.0K | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $2.0M | $541.0K | $235.0K | $177.0K |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | -24.5% | — | — | — | — | — | — | — | 100.0% | — | — | |
| Operating Margin % | -4952.0% | — | — | — | — | — | — | — | -38.8% | — | — | |
| Net Margin % | -11023.9% | — | — | — | — | — | — | — | -49.4% | — | — | |
| EBITDA Margin % | -4827.5% | — | — | — | — | — | — | — | -28.9% | — | — | |
| FCF Margin % | -4901.6% | — | — | — | — | — | — | — | -74.1% | — | — | |
| ROE % | -181.3% | -99.3% | -110.0% | -140.5% | -338.0% | -298.1% | 338.3% | 75.5% | 12.9% | 50.3% | -42.5% | |
| ROA % | -89.6% | -85.6% | -93.0% | -86.3% | -130.6% | -147.8% | -170.7% | -996.1% | -105.6% | -113.8% | -13.0% | |
| ROIC % | -38.7% | -95.5% | -109.5% | -97.3% | -132.2% | -118.2% | -1260.9% | 92.8% | 13.9% | 59.0% | -17.8% | |
| R&D / Revenue % | 2786.1% | — | — | — | — | — | — | — | 56.3% | — | — |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | -100.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -100.0% | |
| Gross Profit | 82.0% | -112.0% | -453.8% | -158.8% | -2.1% | -68.1% | 27.6% | 100.0% | 0.0% | -100.0% | |
| Operating Income | 51.5% | -449.0% | -130.4% | -7.6% | 41.8% | -43.9% | 18.7% | 49.8% | 85.7% | -160.9% | |
| Net Income | 54.2% | -156.6% | -122.4% | -7.8% | 32.0% | -93.0% | 46.0% | 52.7% | 81.6% | -90.7% | |
| EPS (Diluted) | 68.0% | 43.5% | 69.4% | 8.1% | 35.5% | -10.7% | 56.4% | 60.2% | 87.3% | 42.2% | |
| Operating Cash Flow | 49.9% | -333.5% | -96.8% | -25.6% | 28.5% | -24.3% | 9.0% | 55.0% | 67.1% | -34.2% | |
| Free Cash Flow | 50.8% | -339.9% | -95.4% | -24.8% | 28.6% | -24.6% | 9.1% | 55.1% | 67.1% | 100.0% | |
| R&D Expense | -54.3% | 684.7% | 24.9% | 26.1% | -43.5% | 56.9% | 3.6% | -63.8% | -58.4% | -14.6% | |
| SG&A Expense | -52.4% | 177.5% | 564.5% | -8.0% | -40.9% | 29.5% | -45.9% | -13.1% | -39.6% | -35.6% | |
| Total Assets | -52.8% | 168.6% | 104.6% | 16.2% | -55.1% | 70.5% | -53.2% | -91.9% | 73.8% | 77.1% | |
| Book Value / Share | -73.5% | -4.4% | -69.2% | -28.1% | -73.2% | 25.5% | -138.5% | -78.7% | 26.4% | 85.1% | |
| Debt | 0.0% | 0.0% | 0.0% | 0.0% | -23.6% | 11.8% | -0.5% | -70.4% | 64.4% | -84.7% | |
| Diluted Shares | 41.0% | 389.8% | 551.9% | 17.3% | 5.4% | 74.4% | 23.9% | 18.7% | 46.2% | 228.5% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B1.82
10Y Low / Med / High0.01 / 0.03 / 0.10
EV/EBITDA2.35
10Y Low / Med / High0.12 / 0.40 / 1.18
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$1.22
Tangible Book / Share
$6.84
Net Current Assets / Share
$13.51
Graham Net-Net
$6.63
Cash / Share
$9.13
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -0.00 | -0.01 | -0.02 | -0.02 | -0.03 | -0.03 | -0.06 | -0.15 | -1.19 | -2.06 | -8.18 | |
| P/S Ratio | 0.34 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.59 | 0.00 | 0.00 | |
| P/B Ratio | 0.01 | 0.01 | 0.02 | 0.03 | 0.10 | 0.08 | -0.20 | -0.11 | -0.15 | -1.04 | 1.82 | |
| EV/EBITDA | 0.22 | 1.18 | 1.02 | 0.12 | 0.40 | 0.42 | 0.12 | -0.36 | -5.54 | -1.73 | 2.35 | |
| EV/Revenue | -10.47 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.60 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
-5.00
Distress
Piotroski F-Score
3
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $0.00 | $173.8M | $0.00 |
| Net Income | -$2.4M | -$2.5M | -$2.4M |
| EPS | $-2.15 | $-2.19 | $-2.17 |
| # Analysts (EPS) | 2 | 2 | 1 |